MARKET

CVM

CVM

CEL SCI
AMEX

Real-time Quotes | Nasdaq Last Sale

18.00
-0.75
-4.00%
After Hours: 18.00 0 0.00% 16:42 03/03 EST
OPEN
19.03
PREV CLOSE
18.75
HIGH
19.50
LOW
18.00
VOLUME
551.80K
TURNOVER
--
52 WEEK HIGH
40.91
52 WEEK LOW
8.10
MARKET CAP
729.53M
P/E (TTM)
-20.5035
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CVM: 1Q:21 Financial Update
By John Vandermosten, CFA NYSE:CVM First Quarter Fiscal Year 2021 Operational and Financial Results CEL-SCI Corporation (NYSE:CVM) posted a press release and filed its 10-Q for its first quarter of fiscal year 2021 in mid-February. Since our previous repor...
Zacks Small Cap Research · 2d ago
BRIEF-CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
reuters.com · 02/16 14:21
Cel-Sci reports FQ1 results
Cel-Sci (CVM): FQ1 GAAP EPS of -$0.21.Cash position was ~$21.9M. After Dec. 31, 2020, CEL-SCI has received ~$3.9M through the exercise of warrants and stock options.Shares +1.91% PM.Press Release
Seekingalpha · 02/16 14:10
CEL-SCI Q1 EPS $(0.21) Down From $(0.16) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.21) per share. This is a 31.25 percent decrease over losses of $(0.16) per share from the same period last year.
Benzinga · 02/16 14:05
CEL-SCI 1Q Loss/Shr 21c >CVM
CEL-SCI 1Q Loss/Shr 21c >CVM
Dow Jones · 02/16 14:00
Press Release: CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
Dow Jones · 02/16 14:00
West Nile Virus Testing Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 16, 2021 (Market Insight Reports) -- The report for West Nile Virus Testing offers an assiduous analysis of contemporary market trends, driving factors,...
Market Insight Reports · 02/16 13:45
Cel-Sci Reports Wider Fiscal Q1 Net Loss; Shares Down Over 6%
MT Newswires · 02/16 11:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CVM. Analyze the recent business situations of CEL SCI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CVM stock price target is 23.00 with a high estimate of 23.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 5.85M
% Owned: 14.43%
Shares Outstanding: 40.53M
TypeInstitutionsShares
Increased
19
2.66M
New
30
493.48K
Decreased
4
177.55K
Sold Out
3
243.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chief Executive Officer/Director/Treasurer
Geert Kersten
Senior Vice President/Secretary
Patricia Prichep
Senior Vice President
John Cipriano
Senior Vice President
Daniel Zimmerman
Chief Scientific Officer
Eyal Talor
Independent Director
Bruno Baillavoine
Independent Director
Robert Watson
Independent Director
Peter Young
  • Dividends
  • Splits
  • Insider Activity
No Data
About CVM
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Webull offers kinds of CEL-SCI Corporation stock information, including AMEX:CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.